Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piero Fregatti

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
ESMO Open|August 21, 2020
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort studyEva Blondeaux, Arlindo R Ferreira, Francesca Poggio, et al.
British Journal of Cancer|April 2, 2020
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 studyEva Blondeaux, Matteo Lambertini, Andrea Michelotti, et al.
Journal of the National Cancer Institute|December 1, 2021
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer PatientsMatteo Lambertini, Luca Boni, Andrea Michelotti, et al.
Journal of Translational Medicine|May 3, 2017
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer casesGabriele Zoppoli, Anna Garuti, Gabriella Cirmena, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
Post-Surgical Pyoderma Gangrenosum After Breast Cancer Surgery: A Multidisciplinary Case ReportRaquel Diaz, Rebecca Allievi, Letizia Cuniolo, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Breast Metastasis from Pulmonary Mucoepidermoid Carcinoma in a Male Patient: A Case ReportRaquel Diaz, Letizia Cuniolo, Rebecca Allievi, et al.
In Vivo (Athens, Greece)|March 4, 2022
The Margins' Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast CancerPiero Fregatti, Marco Gipponi, Giulia Atzori, et al.
Cancer Treatment Reviews|September 29, 2024
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancerFederico Rebaudi, Fabiana De Franco, Rayan Goda, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trialBenedetta Conte, Marco Bruzzone, Matteo Lambertini, et al.
Journal of Personalized Medicine|June 25, 2026
Simultaneous Risk-Reducing Mastectomy and Salpingo-Oophorectomy in Patients with <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants: A Single-Center Retrospective Cohort StudyRaquel Diaz, Federica Murelli, Franco Alessandri, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
ESMO Open|August 21, 2020
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort studyEva Blondeaux, Arlindo R Ferreira, Francesca Poggio, et al.
British Journal of Cancer|April 2, 2020
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 studyEva Blondeaux, Matteo Lambertini, Andrea Michelotti, et al.
Journal of the National Cancer Institute|December 1, 2021
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer PatientsMatteo Lambertini, Luca Boni, Andrea Michelotti, et al.
Journal of Translational Medicine|May 3, 2017
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer casesGabriele Zoppoli, Anna Garuti, Gabriella Cirmena, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
Post-Surgical Pyoderma Gangrenosum After Breast Cancer Surgery: A Multidisciplinary Case ReportRaquel Diaz, Rebecca Allievi, Letizia Cuniolo, et al.
Current Oncology (Toronto, Ont.)|February 26, 2026
Breast Metastasis from Pulmonary Mucoepidermoid Carcinoma in a Male Patient: A Case ReportRaquel Diaz, Letizia Cuniolo, Rebecca Allievi, et al.
In Vivo (Athens, Greece)|March 4, 2022
The Margins' Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast CancerPiero Fregatti, Marco Gipponi, Giulia Atzori, et al.
Cancer Treatment Reviews|September 29, 2024
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancerFederico Rebaudi, Fabiana De Franco, Rayan Goda, et al.
European Journal of Cancer (Oxford, England : 1990)|July 8, 2020
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trialBenedetta Conte, Marco Bruzzone, Matteo Lambertini, et al.
Journal of Personalized Medicine|June 25, 2026
Simultaneous Risk-Reducing Mastectomy and Salpingo-Oophorectomy in Patients with <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants: A Single-Center Retrospective Cohort StudyRaquel Diaz, Federica Murelli, Franco Alessandri, et al.
Pageof 7